Select Bibliography

Filter by any of these (after searching):

Rini, B. I.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 4 items

Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

Halabi, S. , Rini, B. I. , Stadler, W. M. , Archer, L. E. ... - ASCO - J Clin Oncol - 2010

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206

Hypertension is associated with clinical outcome for patients (Pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206

Harzstark, A. L. , Halabi, S. , Stadler, W. M. , Vaena, D. A. ... - ASCO GU - Genitourinary Cancers Symposium - 2010

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206

CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma

Rini, B. I. , Halabi, S. , Rosenberg, J. E. , Stadler, W. M. ... - ASCO GU - Genitourinary Cancers Symposium - 2008

Abstract - Primary - Preliminary - GU - CALGB-90206

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206

Rini, B. I. , Halabi, S. , Rosenberg, J. E. , Stadler, W. M. ... - ASCO - J Clin Oncol - 2009

Abstract - Primary - Primary - GU - CALGB-90206